Peapack Gladstone Financial Corp Sells 5,308 Shares of Edwards Lifesciences Co. (NYSE:EW)

Peapack Gladstone Financial Corp decreased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 1.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 288,450 shares of the medical research company's stock after selling 5,308 shares during the quarter. Peapack Gladstone Financial Corp's holdings in Edwards Lifesciences were worth $21,355,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Crowley Wealth Management Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter valued at $26,000. Millstone Evans Group LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the fourth quarter valued at about $30,000. Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $46,000. Finally, Catalyst Capital Advisors LLC purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $54,000. Institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Barclays boosted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. Finally, Piper Sandler upped their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $79.81.

Edwards Lifesciences Trading Up 0.9 %

Shares of Edwards Lifesciences stock traded up $0.60 during trading on Friday, hitting $68.86. The stock had a trading volume of 1,482,930 shares, compared to its average volume of 4,884,205. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market cap of $40.48 billion, a PE ratio of 9.88, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The firm's fifty day simple moving average is $71.36 and its 200-day simple moving average is $70.67.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 400 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the completion of the sale, the vice president now owns 22,588 shares of the company's stock, valued at $1,569,414.24. This represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,853 shares of company stock valued at $4,534,247. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.